Erschienen in:
01.10.2001 | Adis New Drug Profile
Cisplatin/Epinephrine Injectable Gel
A Viewpoint by Maurie Markman
verfasst von:
Maurie Markman
Erschienen in:
Drugs & Aging
|
Ausgabe 10/2001
Einloggen, um Zugang zu erhalten
Excerpt
While cytotoxic chemotherapy (e.g. cisplatin) can decrease the size of neoplastic lesions, these agents can be associated with significant systemic toxicity. The local administration of cisplatin (in an epinephrine-containing gel) has the potential to increase the exposure of a symptomatic cancerous mass to the antineoplastic drug, while at the same time decreasing adverse effects. This strategy is particularly relevant in those settings where other local management approaches are unable to be utilised (e.g. surgery, external beam radiation), where cisplatin is known to be an active agent (e.g. breast cancer, head and neck malignancies) and where it is anticipated that systemic drug delivery will be ineffective due to inadequate blood supply (e.g. tumour exposed to prior radiation therapy, necrotic poorly vascularised tumour). …
